CME in the 13F filings
Cme Group Inc · CUSIP 12572Q105
- Quarter end
- 30 Sep 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 29 Oct 2025
- Managers listing it
- 33
- at least, of 95 tracked, among listed positions
- Comparable managers
- 95
- filed both Q2 2025 and Q3 2025; 29 listed it in both
- Shares listed
- 43,897,496
- combined, among listed positions
- Reported value
- $11.9bn
- combined, at the quarter end
Among the 95 comparable managers: 14 buyers (opened or added shares) and 17 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing CME in Q3 2025
33 of 33 holders
Largest increases and reductions, by shares
Increases
- T. Rowe Price Associates Incexisting position · 7,361,208 shares now+1,605,469
- Janus Henderson Group Ltdexisting position · 1,812,202 shares now+565,359
- Invesco Ltdexisting position · 2,830,323 shares now+528,358
- AllianceBernstein LPexisting position · 1,570,658 shares now+437,552
- Holocene Advisors LPnew position · 268,588 shares now+268,588
Reductions
- Arrowstreet Capital LPexisting position · 2,866,455 shares now-966,635
- Two Sigma Advisers LPexisting position · 916,200 shares now-925,216
- Two Sigma Investments LPexisting position · 301,119 shares now-523,371
- Capital World Investorsexisting position · 8,271,156 shares now-345,412
- Egerton Capital UK LLPexisting position · 1,184,788 shares now-338,148
New positions and exits
New (2)
Exited (1)
- Viking Global Investors LPwas $165m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 23 | $5.0bn | n.a. | n.a. |
| Q3 2013 | 21 | $5.0bn | n.a. | n.a. |
| Q4 2013 | 19 | $4.5bn | n.a. | n.a. |
| Q1 2014 | 18 | $4.2bn | n.a. | n.a. |
| Q2 2014 | 19 | $4.2bn | n.a. | n.a. |
| Q3 2014 | 18 | $5.1bn | n.a. | n.a. |
| Q4 2014 | 19 | $5.6bn | n.a. | n.a. |
| Q1 2015 | 22 | $5.8bn | n.a. | n.a. |
| Q2 2015 | 22 | $5.5bn | n.a. | n.a. |
| Q3 2015 | 25 | $5.2bn | n.a. | n.a. |
| Q4 2015 | 24 | $4.9bn | n.a. | n.a. |
| Q1 2016 | 26 | $5.4bn | n.a. | n.a. |
| Q2 2016 | 29 | $6.0bn | n.a. | n.a. |
| Q3 2016 | 27 | $5.8bn | n.a. | n.a. |
| Q4 2016 | 30 | $6.3bn | n.a. | n.a. |
| Q1 2017 | 30 | $6.4bn | n.a. | n.a. |
| Q2 2017 | 35 | $7.0bn | n.a. | n.a. |
| Q3 2017 | 31 | $7.7bn | n.a. | n.a. |
| Q4 2017 | 30 | $7.8bn | n.a. | n.a. |
| Q1 2018 | 33 | $8.8bn | n.a. | n.a. |
| Q2 2018 | 32 | $9.9bn | n.a. | n.a. |
| Q3 2018 | 30 | $10.5bn | n.a. | n.a. |
| Q4 2018 | 27 | $12.4bn | n.a. | n.a. |
| Q1 2019 | 31 | $12.0bn | n.a. | n.a. |
| Q2 2019 | 28 | $14.6bn | n.a. | n.a. |
| Q3 2019 | 29 | $16.0bn | n.a. | n.a. |
| Q4 2019 | 28 | $15.3bn | n.a. | n.a. |
| Q1 2020 | 32 | $13.4bn | n.a. | n.a. |
| Q2 2020 | 32 | $12.2bn | n.a. | n.a. |
| Q3 2020 | 32 | $11.8bn | n.a. | n.a. |
| Q4 2020 | 26 | $11.4bn | n.a. | n.a. |
| Q1 2021 | 26 | $12.3bn | n.a. | n.a. |
| Q2 2021 | 26 | $12.8bn | n.a. | n.a. |
| Q3 2021 | 30 | $11.6bn | n.a. | n.a. |
| Q4 2021 | 26 | $14.6bn | n.a. | n.a. |
| Q1 2022 | 32 | $15.8bn | n.a. | n.a. |
| Q2 2022 | 37 | $13.4bn | n.a. | n.a. |
| Q3 2022 | 38 | $10.9bn | n.a. | n.a. |
| Q4 2022 | 36 | $9.1bn | n.a. | n.a. |
| Q1 2023 | 32 | $9.6bn | n.a. | n.a. |
| Q2 2023 | 34 | $9.5bn | n.a. | n.a. |
| Q3 2023 | 33 | $9.8bn | n.a. | n.a. |
| Q4 2023 | 32 | $10.2bn | 18 | 14 |
| Q1 2024 | 30 | $8.9bn | 13 | 16 |
| Q2 2024 | 33 | $8.3bn | 20 | 11 |
| Q3 2024 | 35 | $10.0bn | 22 | 12 |
| Q4 2024 | 35 | $11.1bn | 16 | 15 |
| Q1 2025 | 35 | $12.1bn | 21 | 13 |
| Q2 2025 | 37 | $12.7bn | 18 | 17 |
| Q3 2025 | 33 | $11.9bn | 14 | 17 |
| Q4 2025 | 31 | $11.1bn | 20 | 26 |
| Q1 2026 | 33 | $11.4bn | 15 | 26 |
| Q2 2026 | 37 | $9.3bn | 31 | 13 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
CME and V →CME and AXP →CME and BAC →Choose a stock to compare with CME →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own CME, latest filings →Back to the 13F Explorer →